Hour TC - Search Results

1

Involvement of p38 mitogen-activated protein kinase in acquired gemcitabine-resistant human urothelial carcinoma sublines.

Kao YT, Hsu WC, Hu HT, Hsu SH, Lin CS, Chiu CC, Lu CY, Hour TC, Pu YS, Huang AM. Kao YT, et al. Among authors: hour tc. Kaohsiung J Med Sci. 2014 Jul;30(7):323-30. doi: 10.1016/j.kjms.2014.03.004. Epub 2014 Apr 17. Kaohsiung J Med Sci. 2014. PMID: 24924837 Free article.

2

Kaempferol-Enhanced Migration and Differentiation of C2C12 Myoblasts via ITG1B/FAK/Paxillin and IGF1R/AKT/mTOR Signaling Pathways.

Hour TC, Lan Nhi NT, Lai IJ, Chuu CP, Lin PC, Chang HW, Su YF, Chen CH, Chen YK. Hour TC, et al. Mol Nutr Food Res. 2024 Jul;68(14):e2300685. doi: 10.1002/mnfr.202300685. Epub 2024 Jun 11. Mol Nutr Food Res. 2024. PMID: 38860356

3

Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation.

Hour TC, Chen J, Huang CY, Guan JY, Lu SH, Pu YS. Hour TC, et al. Prostate. 2002 May 15;51(3):211-8. doi: 10.1002/pros.10089. Prostate. 2002. PMID: 11967955

4

Arsenic trioxide as a novel anticancer agent against human transitional carcinoma--characterizing its apoptotic pathway.

Pu YS, Hour TC, Chen J, Huang CY, Guan JY, Lu SH. Pu YS, et al. Among authors: hour tc. Anticancer Drugs. 2002 Mar;13(3):293-300. doi: 10.1097/00001813-200203000-00011. Anticancer Drugs. 2002. PMID: 11984073

5

Cytotoxicity of arsenic trioxide to transitional carcinoma cells.

Pu YS, Hour TC, Chen J, Huang CY, Guan JY, Lu SH. Pu YS, et al. Among authors: hour tc. Urology. 2002 Aug;60(2):346-50. doi: 10.1016/s0090-4295(02)01699-0. Urology. 2002. PMID: 12137851

6

Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells.

Pu YS, Hour TC, Chuang SE, Cheng AL, Lai MK, Kuo ML. Pu YS, et al. Among authors: hour tc. Prostate. 2004 Jul 1;60(2):120-9. doi: 10.1002/pros.20057. Prostate. 2004. PMID: 15162378

7

Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide.

Hour TC, Huang CY, Lin CC, Chen J, Guan JY, Lee JM, Pu YS. Hour TC, et al. Anticancer Drugs. 2004 Sep;15(8):779-85. doi: 10.1097/00001813-200409000-00007. Anticancer Drugs. 2004. PMID: 15494640

8

Resistance to paclitaxel is proportional to cellular total antioxidant capacity.

Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ, Pu YS. Ramanathan B, et al. Among authors: hour tc. Cancer Res. 2005 Sep 15;65(18):8455-60. doi: 10.1158/0008-5472.CAN-05-1162. Cancer Res. 2005. PMID: 16166325

9

Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells.

Pu YS, Hsieh MW, Wang CW, Liu GY, Huang CY, Lin CC, Guan JY, Lin SR, Hour TC. Pu YS, et al. Among authors: hour tc. Biochem Pharmacol. 2006 Mar 14;71(6):751-60. doi: 10.1016/j.bcp.2005.12.009. Epub 2006 Jan 18. Biochem Pharmacol. 2006. PMID: 16413505

10

Differential expression of molecular markers in arsenic- and non-arsenic-related urothelial cancer.

Hour TC, Pu YS, Lin CC, Huang SW, Chen J, Chiu AW, Chen CJ, Huang CY. Hour TC, et al. Anticancer Res. 2006 Jan-Feb;26(1A):375-8. Anticancer Res. 2006. PMID: 16475721 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

84 results

Search Page

Filters